In conclusion, advanced knowledge of rejection and immunosuppression will almost certainly lead to the clinical use of xenografts in the not too distant future. The immunosuppressants currently used may be sufficient to control rejection, but new drugs are required to prevent hyperacute rejection and graft damage. The use of animals with genetically altered endothelial cells may eliminate hyperacute rejection.102,104.
|Original language||English (US)|
|Number of pages||17|
|Journal||Seminars in Anesthesia, Perioperative Medicine and Pain|
|State||Published - Jan 1 1995|
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine